Targeting PPAR ligands as possible approaches for metabolic reprogramming of T cells in cancer immunotherapy

Despite the prominent progress in understanding cancer immunosurveillance mechanisms, there are some types
of problems which have been identified to hinder effective and successful immunotherapy of cancers. Such
problems have been ascribed to the tumor abilities in the creation of a tolerant milieu that can impair immune
responses against cancer cells. In the present study, we represent possible approaches for metabolic repro-
gramming of T cells in cancer immunotherapy to overcome tumor metabolic impositions on immune responses
against cancer cells. Metabolic suppression of effector immune cells in tumor milieu is one of the important
strategies recruited by tumor cells to escape from immunogenic cell death. We have investigated the metabolic
reprogramming of T cells as a method and a possible new target for cancer immunotherapy. Synergic effects of
PPAR ligands in immunotherapy of cancers on the metabolic reprogramming of T cells have been noticed by
several studies as a new target of cancer immunotherapy. The current wealth of data like this promises a future
scenario which the consideration of metabolic restriction in the tumor microenvironment and administration of
therapeutic agents such as PPAR ligands to overcome metabolic restrictions on T cells (refreshing their func-
tionality) may be effective and enhance the accountability and efficacy of cancer immunotherapy.